Billiontoone (NASDAQ:BLLN) Stock Price Target Raised at JPMorgan Chase & Co.

Billiontoone (NASDAQ:BLLN) had its target price upped by research analysts at JPMorgan Chase & Co. from $130.00 to $135.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 20.12% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. BTIG Research reissued a “buy” rating and set a $130.00 target price on shares of Billiontoone in a research note on Thursday. Zacks Research upgraded Billiontoone from a “strong sell” rating to a “hold” rating in a research note on Friday, October 2nd. Canaccord Genuity Group started coverage on Billiontoone in a report on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 price target for the company. Weiss Ratings downgraded Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Finally, Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Billiontoone presently has a consensus rating of “Moderate Buy” and a consensus price target of $126.88.

Billiontoone Stock Performance

Shares of BLLN traded down $1.50 during trading hours on Thursday, hitting $112.39. The stock had a trading volume of 1,684,843 shares, compared to its average volume of 552,173. The firm has a 50-day moving average price of $104.67 and a 200 day moving average price of $96.89. Billiontoone has a fifty-two week low of $61.96 and a fifty-two week high of $150.44. The firm has a market capitalization of $5.30 billion and a price-to-earnings ratio of 160.56. The company has a debt-to-equity ratio of 0.17, a quick ratio of 11.31 and a current ratio of 11.69.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, meeting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The company had revenue of $109.45 million for the quarter. As a group, research analysts anticipate that Billiontoone will post 0.80 EPS for the current year.

Insider Buying and Selling at Billiontoone

In other news, insider Thomas P. Lynch sold 35,112 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $110.33, for a total transaction of $3,873,906.96. Following the completion of the sale, the insider owned 700 shares of the company’s stock, valued at $77,231. The trade was a 98.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Oguzhan Atay sold 25,001 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $109.24, for a total transaction of $2,731,109.24. Following the transaction, the chief executive officer owned 16,667 shares of the company’s stock, valued at approximately $1,820,703.08. This trade represents a 60.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 264,194 shares of company stock valued at $27,797,333 over the last ninety days. Corporate insiders own 50.22% of the company’s stock.

Institutional Investors Weigh In On Billiontoone

Institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC purchased a new stake in Billiontoone during the 2nd quarter worth approximately $29,000. Parallel Advisors LLC raised its holdings in shares of Billiontoone by 86.7% during the third quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $30,000 after acquiring an additional 130 shares during the last quarter. Family Legacy Financial Solutions LLC acquired a new position in shares of Billiontoone during the third quarter valued at approximately $53,000. MCF Advisors LLC lifted its position in shares of Billiontoone by 330.8% in the second quarter. MCF Advisors LLC now owns 448 shares of the company’s stock valued at $54,000 after acquiring an additional 344 shares in the last quarter. Finally, Provenance Wealth Advisors LLC purchased a new position in shares of Billiontoone in the third quarter valued at approximately $56,000.

Key Headlines Impacting Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results beat estimates: Revenue was about $123 million, ahead of the $115.8 million estimate, and earnings per share also exceeded consensus. BillionToOne Q3 results and guidance
• Positive Sentiment: Higher full-year outlook and upcoming product launch: BillionToOne raised its 2026 revenue guidance to $460 million–$470 million and said it plans to launch Northstar Clear on December 15, supporting expectations for growth. Revenue outlook and Northstar Clear launch
• Neutral Sentiment: BTIG maintained a Buy rating: The firm’s $130 target implies potential upside from the price cited in the report, but it lowered the target from $142, tempering the positive signal. BTIG Research rating
• Negative Sentiment: Executives reported share sales: The CEO, CTO and an SVP sold shares. The transactions were made under pre-arranged Rule 10b5-1 plans, though insider sales can still raise investor concerns about near-term sentiment. Insider transaction report

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.